Search results for "AMA"

showing 10 items of 8558 documents

Oxidative Stress in Diabetic Retinopathy

2021

Diabetic Retinopathy (DR) is a progressive asymptomatic neuro-vascular complication of diabetes that triggers irreversible retinal damage [...]

medicine.medical_specialtygenetic structuresPhysiologybusiness.industryRetinal damagelcsh:RM1-950Clinical BiochemistryCell BiologyDiabetic retinopathymedicine.diseasemedicine.disease_causeBiochemistryAsymptomaticEditorialn/alcsh:Therapeutics. PharmacologyOphthalmologyDiabetes mellitusmedicinemedicine.symptombusinessComplicationMolecular BiologyOxidative stressAntioxidants
researchProduct

Pseudomelanome der Aderhaut

2007

BACKGROUND: The aim of this study was to evaluate what are the most frequent ocular diseases that were suspected for choroidal melanoma (”pseudo melanoma”). PATIENTS AND METHODS: The data of all patients who were seen in the University Hospital of Mainz under the suspicion of choroidal melanoma between 1.1.1994 and 1.1.2004 and underwent ultrasound examination, fluorescein angiography or fundus photography, were analysed retrospectively. Among 458 examined eyes a choroidal melanoma was diagnosed in 212 cases. In 246 cases the diagnosis was “pseudomelanoma”. RESULTS: The most frequent ocular diseases suspected for choroidal melanoma were “suspicious nevi” in 31 % of the cases and “disciforme…

medicine.medical_specialtygenetic structuresmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentFundus photographyVitrectomyFundus (eye)Fluorescein angiographymedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structureOphthalmologymedicineHamartomaPseudomelanomasense organsChoroidbusinessScleritisKlinische Monatsblätter für Augenheilkunde
researchProduct

Validation study of Italian version of inventory for déjà vu experiences assessment (I-IDEA): A screening tool to detect déjà vu phenomenon in Italia…

2017

The Inventory Déjà Vu Experiences Assessment (IDEA) is the only screening instrument proposed to evaluate the Déjà vu (DV) experience. Here, we intended to validate the Italian version of IDEA (I-IDEA) and at the same time to investigate the incidence and subjective qualities of the DV phenomenon in healthy Italian adult individuals on basis of an Italian multicentre observational study. In this study, we report normative data on the I-IDEA, collected on a sample of 542 Italian healthy subjects aging between 18-70 years (average age: 40) with a formal educational from 1-19 years. From September 2013 to March 2016, we recruited 542 healthy volunteers from 10 outpatient neurological clinics i…

medicine.medical_specialtylcsh:BF1-990Inventory for Déjà Vu Experiences Assessment (IDEA)Development050105 experimental psychology03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineInformed consentJamais vuDepersonalizationGeneticsmedicine0501 psychology and cognitive sciencesPsychiatryGeneral PsychologyEcology Evolution Behavior and SystematicsBrief ReportIncidence (epidemiology)05 social sciencesTest (assessment)Prevalence of DVlcsh:PsychologyDéjà vu; Inventory for Déjà Vu Experiences Assessment (IDEA); Prevalence of DVDéjà vuDéjà vuNormativeObservational studymedicine.symptomPsychology030217 neurology & neurosurgery
researchProduct

Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

2009

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Commit

medicine.medical_specialtymanagement arterial hypertensionPhysiologyupdateRenal functionBlood PressureInternal medicinemedicineInternal MedicineHumanscardiovascular diseasesAntihypertensive AgentsTask forcebusiness.industryHypertension GuidelineHypertension managementGeneral MedicineEuropeOrgan damageBlood pressureHypertensionPractice Guidelines as Topiccardiovascular systemCardiologyMED/09 - MEDICINA INTERNAbusinessEndothelin receptorCardiology and Cardiovascular Medicine
researchProduct

Health and Demographic Characteristics of Patients Attending a Newly-Opened Medical Facility in a Remote Amazonian Community: A Descriptive Study

2018

Peru is a country with wide regional disparities in health. Remote Amazonian communities have high rates of poverty and poor access to health services. There is a lack of data on morbidity and use of health services in the region. We describe a descriptive, cross-sectional study of the demographic characteristics and presenting complaints of attendees to a newly-opened primary care facility in a remote community. This was supplemented by structured interviews of adult attendees to build a picture of sociocultural determinants of health locally, including engagement with traditional forms of medicine. Our study provides novel insights into an under-studied and under-resourced area. We found …

medicine.medical_specialtymedia_common.quotation_subject030231 tropical medicinelcsh:Medicinetraditional medicineArticleLiteracy03 medical and health sciences0302 clinical medicineHealth carehealth-seeking behaviourMedicinerural health030212 general & internal medicineSocial determinants of healthAmazonmedia_commonPovertybusiness.industryRural healthlcsh:RFamily medicinehealth beliefsStructured interviewDescriptive researchbusinessPrimary care facilityMedical Sciences
researchProduct

Pre-operative diclofenac HPβCD for pain control of needle biopsy in musculoskeletal neoplasm: preliminary results.

2015

Needle biopsy is the main standard method used for diagnosis of musculoskeletal tumors of the limbs and superficial trunk. Pain control during this procedure is through the use of Local Anaestetic (L.A.). In order to achieve a complete pain control in our cases, recently we started using diclofenac HPβCD 50 mg via s.c. preoperativly. We present the clinical results of a non-randomized study of two eterogeneous groups of patients: "Experimental" Group (1): diclofenac HPβCD 50 mg via s.c. one hour before surgical procedure, local anesthesia and ev. diclofenac HPβCD 50 mg via s.c. 12 hours postoperative; "Conventional" Group (2): local anesthesia and ev. postoperative tramadol 100 mg via oral …

medicine.medical_specialtymedicine.diagnostic_testLocal anestheticmedicine.drug_classbusiness.industryPerforation (oil well)Chronic painPerioperativemedicine.diseaseSurgeryDiabetes and MetabolismDiclofenac HPβCD s.cEndocrinologyDiclofenacBiopsyInternal MedicinemedicineLocal anesthesiaOriginal ArticleTramadolbusinessNeedle biopsy musculoskeletal neoplasmDiclofenac HPβCD s.c.; Needle biopsy musculoskeletal neoplasm; Pain control; Endocrinology Diabetes and Metabolism; Internal MedicinePain controlmedicine.drugClinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
researchProduct

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension deliver…

2018

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD. Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while retaining a safety profile similar to LAMA or LABA alone. This has led to the development of several LAMA/LABA fixed-dose combination (FDC) therapies, which provide patients with the convenience of two active compounds in a single inhaler. GFF MDI (Bevespi Aerosphere®) is an FDC of glycopyrrolate/formote…

medicine.medical_specialtymedicine.drug_classDrug CompoundingFixed-dose combinationMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineFormoterol FumarateBronchodilatorAdministration InhalationmedicineHumans030212 general & internal medicineIntensive care medicineAdrenergic beta-2 Receptor AgonistsGlycopyrrolateCOPDbiologybusiness.industryInhalerGeneral MedicineLamamedicine.diseasebiology.organism_classificationGlycopyrrolateMetered-dose inhalerBronchodilator AgentsDrug CombinationsTreatment Outcome030228 respiratory systemFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor

2002

(-)-(3aS,8aS,1S)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol-2′-ethylphenylcarbamate N-oxide hydrochloride (CHF2819) is a novel, orally active acetylcholinesterase inhibitor (AChEI) for Alzheimer's disease (AD). CHF2819 appears as a selective inhibitor of AChE, being 115 times more potent against this enzyme than butyrylcholinesterase (BuChE). Moreover, CHF2819 appears more selective for inhibiting central (brain) than peripheral (heart) AChE. In vivo studies show that CHF2819 significantly increases acetylcholine (ACh) levels in young adult rat hippocampus in a dose-dependent manner. Moreover, aged animals exhibit a marked increase in hippocampal concentrations of this…

medicine.medical_specialtymedicine.drug_classGlutamate receptorBiologyAcetylcholinesterasechemistry.chemical_compoundEndocrinologychemistryAcetylcholinesterase inhibitorDopamineEnzyme inhibitorInternal medicineDrug Discoverymedicinebiology.proteinNeurotransmitterAcetylcholineButyrylcholinesterasemedicine.drugDrug Development Research
researchProduct

CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor

2002

CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…

medicine.medical_specialtymedicine.drug_classPhenylcarbamatesPharmacologyHippocampusArticleCyclic N-Oxideschemistry.chemical_compoundNeurochemicalAlzheimer DiseaseDopamineInternal medicinemedicineAnimalsBiogenic MonoaminesAmino AcidsNeurotransmitterButyrylcholinesteraseCholinesterasePharmacologybiologybusiness.industryGlutamate receptoracetylcholinesterase inhibitors; alzheimer's disease; amino acids; chf2819; ganstigmine; neurotransmitters; rat hippocampusAcetylcholineRatsNeuropsychology and Physiological PsychologyEndocrinologyAcetylcholinesterase inhibitorchemistrybiology.proteinCarbamatesCholinesterase InhibitorsbusinessAcetylcholinemedicine.drug
researchProduct

<p>Future perspectives of anticholinergics for the treatment of asthma in adults and children</p>

2019

Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinic…

medicine.medical_specialtymedicine.drug_classPsychological intervention030204 cardiovascular system & hematologyAsthma managementPlacebo03 medical and health sciences0302 clinical medicineAnticholinergicMedicinePharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsDisease management (health)Intensive care medicineAsthmaChemical Health and Safetybiologybusiness.industryGeneral MedicineLamabiology.organism_classificationmedicine.diseaserespiratory tract diseasesClinical trialbusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct